GT BIOPHARMA, INC. — Net Income by Fiscal Year
16 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/0a1134e9-e5a5-45f6-97aa-a0fad2861b35/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-28.4M | 2025-01-01 – 2025-12-31 | evidence 0001493152-26-008443 |
| FY 2024 | $-13.2M | 2024-01-01 – 2024-12-31 | evidence 0001493152-25-007908 |
| FY 2023 | $-7.6M | 2023-01-01 – 2023-12-31 | evidence 0001493152-24-011332 |
| FY 2022 | $-20.9M | 2022-01-01 – 2022-12-31 | evidence 0001493152-23-009812 |
| FY 2021 | $-58.0M | 2021-01-01 – 2021-12-31 | evidence 0001493152-22-007883 |
| FY 2020 | $-28.3M | 2020-01-01 – 2020-12-31 | evidence 0001654954-21-004295 |
| FY 2019 | $-38.6M | 2019-01-01 – 2019-12-31 | evidence 0001654954-20-003380 |
| FY 2018 | $-259.2M | 2018-01-01 – 2018-12-31 | evidence 0001654954-19-003697 |
| FY 2017 | $-144.2M | 2017-01-01 – 2017-12-31 | evidence 0001654954-19-003697 |
| FY 2016 | $9.8M | 2016-01-01 – 2016-12-31 | evidence 0001654954-18-001973 |
| FY 2015 | $-21.5M | 2015-01-01 – 2015-12-31 | evidence 0001654954-18-001969 |
| FY 2014 | $-23.5M | 2014-01-01 – 2014-12-31 | evidence 0001513160-15-000022 |
| FY 2013 | $-501.0k | 2013-01-01 – 2013-12-31 | evidence 0001513160-15-000005 |
| FY 2012 | $-5.2M | 2012-01-01 – 2012-12-31 | evidence 0001513160-14-000064 |
| FY 2011 | $-3.7M | 2011-01-01 – 2011-12-31 | evidence 0001513160-12-000030 |
| FY 2010 | $-3.0M | 2010-01-01 – 2010-12-31 | evidence 0001513160-12-000030 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).